Difference between revisions of "Rowett Research Institute"
Mary Spowart (talk | contribs) |
Mary Spowart (talk | contribs) |
||
| Line 8: | Line 8: | ||
The Institute was established in 1913 with John Boyd Orr as its first Director. It is an independent Company with Charitable status and receives funding from the Scottish Government Rural and Environment Research and Analysis Directorate. | The Institute was established in 1913 with John Boyd Orr as its first Director. It is an independent Company with Charitable status and receives funding from the Scottish Government Rural and Environment Research and Analysis Directorate. | ||
| + | |||
| + | |||
| + | == [[Rowett Research Services Limited]] == | ||
| + | |||
| + | |||
| + | The Institute created created [[Rowett Research Services Limited]]a private company that is, in its own words " is the knowledge transfer arm of the Rowett Research Institute and offers technology transfer, collaborative and contract research to the pharmaceutical, biotechnology, food and related industries. " | ||
| + | It offer " customer service centred approach that combines technical, project and intellectual property management together with marketing skills to facilitate commercial development of intellectual property and foster links between industry and the science community." {{ref1}} | ||
| + | |||
| + | Rowett Research services aer them further browj donw into four companies {{ref2}} | ||
| + | |||
| + | The Companies : | ||
| + | |||
| + | * [[Provexis plc]] a specialist developer of health drinks for the food and nutraceutical industries. Formed initially in 2000 as [[Nutrition Enhancement Limited]], a joint venture between A[[ngle Technologies plc]] and Rowett, the company took its present name in 2003. | ||
| + | |||
| + | * [[PyrroNostics Lmited]] was created in 2003 and is a developer of novel diagnostic tools for the early detection of chronic disease. The company was formed jointly between Rowett and Immunodiagnostic Systems plc (www.idsltd.com) a leading manufacturer and distributor of diagnostic kits based at Newcastle–upon-Tyne. The company is centred on a discovery by Dr Simon Robins (S.Robins@rowett.ac.uk) that one of the results of cellular breakdown is the production of pyrrole based compounds and that individual structures of pyrroles are often linked biomarkers for specific chronic disorders and that their presence in blood and urine can precede observable clinicaI symptoms. Utilising its seed funding and a Scottish Executive SMART award PyrroNostics is currently working towards proof of principal in a number of disorders. | ||
| + | |||
| + | |||
| + | NovaBiotics Limited (www.novabiotics.co.uk) was formed in 2004 and has taken nature as a model to develop novel antimicrobials for conditions where there are no effective, safe or resistance free treatments. Their first lead product is a topical anti fungal for nail fungus and is based upon a discovery made by immunologist, Dr Deborah O’Neil who is now Chief Scientific Officer for NovaBiotics as a result of work on the body’s mechanisms for fighting infection. The company has recently strengthened its management team which now includes Mr John Pool and with support from a number of investors including Scottish Enterprise Business Growth Fund (www.scottish-enterprise.com) the company is currently progressing preclinical and clinical development of its lead polypeptide product whilst undertaking work to strengthen its future pipeline. | ||
| + | |||
| + | |||
| + | Antoxis Limited (www.antoxis.com) was formed in 2006 and is developing novel products through an informed approach to target and destroy free radicals produced in excessive amounts in a number of neuro degenerative diseases. The company originates from research undertaken by Donald McPhail, now Chief Scientific Officer and Professor Garry Duthie and takes nature as a model for improving antioxidant performance for therapeutic applications. Precompany development has been supported amongst other by Scottish Enterprise (www.scottish-enterprise.com) and RSE (Royal Society of Edinburgh). With funding support from Genomia Seed Fund (www.genomia.org.uk) Antoxis is currently progressing its first lead compound, targeted for stroke, through preclinical development whilst strengthening its future pipeline. | ||
| + | |||
| Line 37: | Line 59: | ||
Chairman of Programme Management Group | Chairman of Programme Management Group | ||
Appointed 2004 | Appointed 2004 | ||
| + | |||
| + | References | ||
| + | |||
| + | # {{note 1}}http://www.rowett.co.uk/ | ||
| + | #{{note 2 }}http://www.rowett.co.uk/rri_companies.html | ||
Revision as of 19:45, 9 October 2007
The Rowett Research Institute is one of four publicly-funded Nutrition Research Institutes in the UK
- Rowett Research Institute (RERAD funded) - Aberdeen
- Institute Food Research (BBSRC funded) - Norwich
- Dunn Human Nutrition Unit (MRC funded) - Cambridge
- Human Nutrition Resources Centre (MRC funded) -Cambridge
The Institute was established in 1913 with John Boyd Orr as its first Director. It is an independent Company with Charitable status and receives funding from the Scottish Government Rural and Environment Research and Analysis Directorate.
Rowett Research Services Limited
The Institute created created Rowett Research Services Limiteda private company that is, in its own words " is the knowledge transfer arm of the Rowett Research Institute and offers technology transfer, collaborative and contract research to the pharmaceutical, biotechnology, food and related industries. " It offer " customer service centred approach that combines technical, project and intellectual property management together with marketing skills to facilitate commercial development of intellectual property and foster links between industry and the science community." Template:Ref1
Rowett Research services aer them further browj donw into four companies Template:Ref2
The Companies :
- Provexis plc a specialist developer of health drinks for the food and nutraceutical industries. Formed initially in 2000 as Nutrition Enhancement Limited, a joint venture between Angle Technologies plc and Rowett, the company took its present name in 2003.
- PyrroNostics Lmited was created in 2003 and is a developer of novel diagnostic tools for the early detection of chronic disease. The company was formed jointly between Rowett and Immunodiagnostic Systems plc (www.idsltd.com) a leading manufacturer and distributor of diagnostic kits based at Newcastle–upon-Tyne. The company is centred on a discovery by Dr Simon Robins (S.Robins@rowett.ac.uk) that one of the results of cellular breakdown is the production of pyrrole based compounds and that individual structures of pyrroles are often linked biomarkers for specific chronic disorders and that their presence in blood and urine can precede observable clinicaI symptoms. Utilising its seed funding and a Scottish Executive SMART award PyrroNostics is currently working towards proof of principal in a number of disorders.
NovaBiotics Limited (www.novabiotics.co.uk) was formed in 2004 and has taken nature as a model to develop novel antimicrobials for conditions where there are no effective, safe or resistance free treatments. Their first lead product is a topical anti fungal for nail fungus and is based upon a discovery made by immunologist, Dr Deborah O’Neil who is now Chief Scientific Officer for NovaBiotics as a result of work on the body’s mechanisms for fighting infection. The company has recently strengthened its management team which now includes Mr John Pool and with support from a number of investors including Scottish Enterprise Business Growth Fund (www.scottish-enterprise.com) the company is currently progressing preclinical and clinical development of its lead polypeptide product whilst undertaking work to strengthen its future pipeline.
Antoxis Limited (www.antoxis.com) was formed in 2006 and is developing novel products through an informed approach to target and destroy free radicals produced in excessive amounts in a number of neuro degenerative diseases. The company originates from research undertaken by Donald McPhail, now Chief Scientific Officer and Professor Garry Duthie and takes nature as a model for improving antioxidant performance for therapeutic applications. Precompany development has been supported amongst other by Scottish Enterprise (www.scottish-enterprise.com) and RSE (Royal Society of Edinburgh). With funding support from Genomia Seed Fund (www.genomia.org.uk) Antoxis is currently progressing its first lead compound, targeted for stroke, through preclinical development whilst strengthening its future pipeline.
Contact Details
- Address: The Rowett Research Institute, Greenburn Road, Bucksburn,
Aberdeen AB21 9SB, Scotland.
- Tel: +44 (0)1224 712751
- Website: http://www.rowett.ac.uk
People
The Institute has a governing body
- Brian Pack OBE, Chairman,appointed 1998
Chief Executive of ANM Group Ltd in November 1990. The Group consists of Aberdeen & Northern Marts, Scotch Premier Meat Ltd, Highland Country Foods Ltd, Yorkshire Premier Meat Ltd, Aberdeen & Northern (Estates) Ltd, Highland Cuisine Ltd, H & I Livestock Ltd,and EASIGOE Ltd. Managing Director of Farmdata Ltd Director of Financial Control Services Ltd Member of Grampian Food Forum, Was awarded an OBE in 1999 for services to agriculture, food and marketing.
- Professor Jonathan Arch appointed 2004
Member of the scientific advisory boards of Biovitrum, Prosidion and Glennmark Pharmaeuticals.
Professor Michael J Gibney Chairman of Programme Management Group Appointed 2004
References
- Template:Note 1http://www.rowett.co.uk/
- Template:Note 2http://www.rowett.co.uk/rri_companies.html
